At Asphalion, we are strongly committed to driving digitalization and integrating innovative tools to enhance our work. We believe that the thoughtful and responsible use of digital solutions, such as Artificial Intelligence, can significantly help improve project outcomes. That’s why we continuously explore new automation strategies to optimize our processes.
The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) are partnering on an ambitious workplan to responsibly integrate artificial intelligence (AI) into the regulation of human and veterinary medicines across the European Medicines Regulatory Network (EMRN).
Spanning 2025 to 2028, this initiative aims to unlock the value of data, enhance regulatory efficiency, and improve decision-making—all while ensuring ethical and trustworthy AI use in line with EU legislation such as the AI Act and GDPR.
Key Highlights of the Workplan:
- Vision and Objectives
- Unlock the full potential of data to support “trusted medicines”
- Integrate AI throughout the entire medicines lifecycle, from development to post-market surveillance
- Promote responsible and ethical AI use aligned with EU regulations
- Focus Areas
- Data-driven regulation: Leveraging real-world evidence, genomics, and AI/machine learning tools for smarter decisions
- AI tools and experimentation: Launching an AI Observatory, establishing an AI Tools framework, and conducting six-month experimentation cycles
- Collaboration and engagement: Creating an AI industry working group and hosting stakeholder events such as hackathons
- Ethical standards: Prioritizing data privacy, cybersecurity, and responsible AI deployment
- Timeline and Actions
- 2025: Publication of responsible AI principles, terminology guide, and network-wide change management strategy
- 2026: Launch of six-month AI experimentation cycles
- 2027: Review experimentation results and develop the AI Tools framework
- Ongoing: Continued expert input through the AI Special Interest Area and expansion of AI training in the Digital Academy
- Regulatory Alignment
- Compliance with EU initiatives such as the European Health Data Space (EHDS), AI Act, and Interoperable Europe Act
- Development of domain-specific guidance, including for AI in pharmacovigilance
- Network Data Steering Group (NDSG)
- Responsible for implementing the workplan and supporting the vision of trusted medicines
- Will review advanced AI methods and new data types to guide future pilots and regulatory use
Why This Matters
This collaboration marks a significant step forward in the digital transformation of medicines regulation in Europe. By embedding AI responsibly into regulatory processes, EMA and HMA aim to accelerate innovation, improve safety monitoring, and ultimately contribute to better public health outcomes.
Stay informed about the evolving landscape of AI in medicines regulation and how it may impact your regulatory strategies.
Need help in your regulatory endeavours? Contact us at: [email protected]
